Literature DB >> 20512044

Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.

Luke C Swenson1, Andrew Moores, Andrew J Low, Alexander Thielen, Winnie Dong, Conan Woods, Mark A Jensen, Brian Wynhoven, Dennison Chan, Christopher Glascock, P Richard Harrigan.   

Abstract

BACKGROUND: Tropism testing should rule out CXCR4-using HIV before treatment with CCR5 antagonists. Currently, the recombinant phenotypic Trofile assay (Monogram) is most widely utilized; however, genotypic tests may represent alternative methods.
METHODS: Independent triplicate amplifications of the HIV gp120 V3 region were made from either plasma HIV RNA or proviral DNA. These underwent standard, population-based sequencing with an ABI3730 (RNA n = 63; DNA n = 40), or "deep" sequencing with a Roche/454 Genome Sequencer-FLX (RNA n = 12; DNA n = 12). Position-specific scoring matrices (PSSMX4/R5) (-6.96 cutoff) and geno2pheno[coreceptor] (5% false-positive rate) inferred tropism from V3 sequence. These methods were then independently validated with a separate, blinded dataset (n = 278) of screening samples from the maraviroc MOTIVATE trials.
RESULTS: Standard sequencing of HIV RNA with PSSM yielded 69% sensitivity and 91% specificity, relative to Trofile. The validation dataset gave 75% sensitivity and 83% specificity. Proviral DNA plus PSSM gave 77% sensitivity and 71% specificity. "Deep" sequencing of HIV RNA detected >2% inferred-CXCR4-using virus in 8/8 samples called non-R5 by Trofile, and <2% in 4/4 samples called R5.
CONCLUSIONS: Triplicate analyses of V3 standard sequence data detect greater proportions of CXCR4-using samples than previously achieved. Sequencing proviral DNA and "deep" V3 sequencing may also be useful tools for assessing tropism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512044     DOI: 10.1097/QAI.0b013e3181d0558f

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  42 in total

1.  Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.

Authors:  A Gonzalez-Serna; R A McGovern; P R Harrigan; F Vidal; A F Y Poon; S Ferrando-Martinez; M A Abad; M Genebat; M Leal; E Ruiz-Mateos
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Authors:  Luke C Swenson; Theresa Mo; Winnie W Y Dong; Xiaoyin Zhong; Conan K Woods; Mark A Jensen; Alexander Thielen; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

3.  Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.

Authors:  Sherry McLaughlin; Luke C Swenson; Shengbo Hu; Paul Hughes; P Richard Harrigan; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-06       Impact factor: 2.205

4.  Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection.

Authors:  Gabriel A Wagner; Mary E Pacold; Edgar Vigil; Gemma Caballero; Sheldon R Morris; Sergei L Kosakovsky Pond; Susan J Little; Douglas D Richman; Sara Gianella; Davey M Smith
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

5.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

7.  Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing.

Authors:  Richard H Liang; Theresa Mo; Winnie Dong; Guinevere Q Lee; Luke C Swenson; Rosemary M McCloskey; Conan K Woods; Chanson J Brumme; Cynthia K Y Ho; Janke Schinkel; Jeffrey B Joy; P Richard Harrigan; Art F Y Poon
Journal:  Nucleic Acids Res       Date:  2014-05-07       Impact factor: 16.971

8.  Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Richard M Gibson; Ariel M Rhea; Justine D Rose; Doug Wylie; Kenneth Henry; Alison Wright; Kevin King; John Archer; Eva Poveda; Vicente Soriano; David L Robertson; Paul D Olivo; Eric J Arts; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

Review 9.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

10.  Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

Authors:  Elise Tu; Luke C Swenson; Sally Land; Sarah Pett; Sean Emery; Kat Marks; Anthony D Kelleher; Steve Kaye; Rolf Kaiser; Eugene Schuelter; Richard Harrigan
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.